bispecific
teplizumab
dorlixizumab
Ab
antisynthetase
countercorrelated
antipolyvalent
polyantibody
zanolimumab
oportuzumab monatox
alacizumab
idiospecific
fontolizumab
soravtansine
-ab
-zumab
polyvalent
immunoprecipitant
ocrelizumab
carlumab
antinucleosome
durvalumab
agonistic monoclonal antibody
cedelizumab
presentation
talizumab
biciromab
sulesomab
mapatumumab
brentuximab
zolimomab
antisubstance
ozoralizumab
-axo-
tigatuzumab
agglutinin
immunospecific
heteroclitic
evolocumab
samalizumab
antigenomic
lucatumumab
conatumumab
immunoprobe
ipilimumab
patritumab
vobarilizumab
hyperimmunized
-a-
nofetumomab